Tuesday, June 5, 2018

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Engagement of Stadnyk & Partners

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement with Stadnyk & Partners whereby PreveCeutical will engage Stadnyk & Partners to provide market awareness and strategic advisory services to the company. Per the terms of the agreement, Stadnyk & Partners will provide market awareness services to the company throughout the initial 12-month term of the agreement in exchange for two million stock options, each of which will be exercisable to acquire one common share in the capital of PreveCeutical for $0.08 per share for a period of 24 months. Stadnyk & Partners will also provide strategic finance, M&A and capital markets advisory services to PreveCeutical to assist it in achieving its business growth goals throughout the term of the agreement, for which the company will issue an additional three million stock options exercisable on the same terms.

To view the full press release, visit http://ibn.fm/aYGXS

About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com

About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments: